Two areas in women’s health where pharmacists play an important role are menopause management and contraception. Assessing women who are having menopausal symptoms and helping women make informed decisions regarding hormone therapy are integral parts of menopause management. Follow-up of women who have started on hormone therapy includes monitoring for symptom improvement, breakthrough bleeding, adverse effects, and adherence to therapy. Initial assessment of the woman for combined hormonal contraceptives (CHC) involves capturing a menstrual history, medical history to screen for CHC contraindications and risks, previous use of contraceptives, and patient preferences for contraception. A baseline blood pressure should also be completed. Women who have started on CHC should be monitored for satisfaction with the chosen method, breakthrough bleeding, adverse effects, and adherence.
KeywordsWomen’s health Menopause Hormone therapy Contraception Hormonal contraceptives
- 3.Portman DJ, Gass ML, Vulvovaginal Atrophy Terminology Consensus Conference P. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063–8.CrossRefGoogle Scholar
- 10.Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015;22(11):1155–72. quiz 73-4.Google Scholar
- 11.Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. Menopause. 2018;25(6):596–608.CrossRefGoogle Scholar
- 15.Black AY, Guilbert E, Hassan F, Chatziheofilou I, Lowin J, Jeddi M, et al. The cost of unintended pregnancies in Canada: estimating direct cost, role of imperfect adherence, and the potential impact of increased use of long-acting reversible contraceptives. J Obstet Gynaecol Can. 2015;37(12):1086–97.CrossRefGoogle Scholar
- 19.World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva, Switzerland: WHO Press; 2015. [cited 2018 February 21]. Available from: http://apps.who.int/iris/bitstream/10665/181468/1/9789241549158_eng.pdf?ua=1.Google Scholar